Fig. 1From: Apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer via the Akt/β-catenin pathwayVEGFR2 expression was elevated in esophageal cancer and associated with the clinical outcome of cisplatin-based treatment. a qPCR analysis of VEGFR2 mRNA expression in 18 paired ESCC tissues and their adjacent non-tumor tissues. VEGFR2 levels were normalized to β-Actin expression. P value was determined by paired t test. b The VEGFR2 protein level in randomly matched tissues of 5 cases was determined by western blotting. β-Actin was used as a control. c Correlation of VEGFR2 mRNA expression with TNM stage. P value was determined by Student’s t-test. d Correlation of VEGFR2 mRNA expression and clinical outcome in 25 advanced esophageal cancer patients who underwent cisplatin-based treatment. CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. P value was determined by Chi-squared testBack to article page